MacroGenics Presents MGC026 Data Showing 27.3% Best Overall Response Rate in Head and Neck Cancer
Bitget2026/10/27 14:08- MacroGenics presented MGC026 data at ESMO showing a 27.3% best overall response rate in 22 heavily pretreated head-and-neck cancer patients.
- Confirmed responses reached 18.2%; the disease control rate was 63.6%.
- No treatment-related discontinuations occurred in the 27-patient expansion cohort; no interstitial lung disease, pneumonitis or ocular toxicity was reported.
- A front-line MGC026-pembrolizumab combination study is planned for early 2027, with the next MGC026 update anticipated mid-2027.
- Pro forma cash equivalents and marketable securities totaled $327 million, supporting a projected cash runway through 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
